Recovery

The role of autophagy in the metabolism and outcomes after surgery, J. Gunst et al.

Fast-track surgery: a multidisciplinary collaboration, H. Kehlet

The patient voice in Enhanced Recovery After Surgery, A. Balfour & R. Alldridge

The role of physiotherapy in Enhanced Recovery after Surgery in the ICU, T.W. Wainwright et al.

Innovations in monitoring: from smartphones to wearables, F. Michard

Physical rehabilitation in the ICU: understanding the evidence, C. M. Goodson et al.

Optimising nutrition for recovery after ICU, P.E. Wischmeyer

Outcomes after 1 week of mechanical ventilation for patients and families, M. Parotto & M.S. Herridge

Continuing rehabilitation after intensive care unit discharge, S. Evans et al.

The hidden faces of sepsis, what do they tell us? I. Nutma-Bade

PLUS

Ultrasound-guided mechanical ventilation, F. Mojoli & S. Mongodi

Haemodynamic monitoring: stuff we never talk about, C. Boerma

Animal-assisted activity in the intensive care unit, M.M. Hosey et al.

From command and control to modern approaches to leadership, T. Dorman

Enabling machine learning in critical care, T.J. Pollard & L.A. Celi
Fibrinogen concentrate in elective complex cardiac surgery

A monocentric trial

Presents the results from a randomised controlled trial which aimed to determine if fibrinogen concentrate infusion reduces intraoperative blood loss in cardiac surgery patients.

Background
Excessive bleeding is a common complication in cardiac surgery, and may result in the need for red blood cell (RBC) transfusion. Intraoperative bleeding during cardiac surgery is often treated with coagulation factor concentrates (CFCs). As yet, however, their efficacy has not been conclusively determined.

Since 1980 our knowledge of damage from transfusion has increased. Risks include infection, effects on the immune system, transfusion-related acute lung injury and risks due to the age of transfused blood (Ishbister et al. 2011). Healthcare systems need to also be aware of the associated costs. As doctors it is our challenge and duty to reduce preventable damage from blood transfusion.

Patient blood management
The evidence-based multidisciplinary approach to optimising care of patients who may need transfusion is known as patient blood management (PBM). We know there is considerable variation in perioperative blood transfusion rate. For example, an analysis of 102,470 patients who underwent coronary artery bypass graft surgery at 792 hospitals in the United States found that rates of blood transfusion ranged from 7.8% to 92.8% for red blood cells (Bennett-Guerrero et al. 2010). PBM can also reduce the need for blood transfusions. In cardiac surgery, a study of Jehovah’s Witnesses, who refuse blood products, found no difference in morbidity and mortality if patients are evaluated with a multidisciplinary approach to blood management (Moraca et al. 2011).

At Isala Clinics, we have researched patient blood management, including tailor-made transfusion protocols (Bilecen et al. 2014), and the role of point-of-care testing and fibrinogen concentrate (Bilecen et al. 2013). We implemented a specific transfusion protocol for cardiac surgery, and conducted an intervention study to evaluate its effects on transfusion and clinical events (Bilecen et al. 2014). The protocol included giving component therapy and fibrinogen at the end of the schedule. If we measured fibrinogen less than 1g/L we added 2g of extra fibrinogen. If it was more than 1g/L based on the Clauss measurement, we did not give fibrinogen. The cardiac surgery-specific transfusion protocol resulted in fewer patients transfused with RBCs and fresh frozen plasma (FFP) and a lower incidence of myocardial infarction.

Fibrinogen concentrate therapy
We conducted a cohort study to evaluate the effect of fibrinogen concentrate therapy on postoperative blood loss and transfusion and occurrence of clinical events in complex cardiac surgery; 264/1075 patients received fibrinogen concentrate during surgery (Bilecen et al. 2013). There was no reduction in postoperative blood loss and transfusion (intensive care unit [ICU] blood loss: OR 1.02 (0.91-1.14) and ICU transfusion: OR 1.14 (0.83-1.56) and no increase in risk for adverse clinical events. However, the haemostatic effect may have been attenuated by the low doses and relatively late administration of fibrinogen concentrate therapy.

Randomised controlled trial
Therefore we initiated a prospective single-centre, randomised, placebo-controlled, double-blind clinical trial to find out if fibrinogen concentrate infusion dosed to achieve a post-infusion plasma fibrinogen level of at least 2.5 g/L in high-risk elective cardiac surgery patients 18 years or over with intraoperative bleeding reduced intraoperative blood loss (Bilecen et al. 2017). The primary outcome of the study was intraoperative blood loss measured between intervention and closure of the chest when surgery ended. Secondary outcomes included the measured blood loss at 1, 3, 6, 12 and 24 hours after the intervention; the proportion of patients who received transfusion; and number of...
The aim was to achieve surgical haemostasis after heparin reversal. It was the surgeons’ decision when to start the 5-minute bleeding time. Once patients had bled for 5 minutes they were entered into the treatment algorithm if they were bleeding >60 mL and <250 mL. The intervention was considered to have started on initiation of infusion of the study medication (Figure 1) (see p. V).

Over the four years of the trial, over 700 patients had complex cardiac surgery, of which 40% were eligible for the trial. Of the eligible patients, 43% did not agree to participate; 203 patients agreed to participate, of which 73 (36%) experienced no intraoperative bleeding and 10 were excluded for other reasons. We suggest that the high number of patients that experienced no intraoperative bleeding may be due to the Hawthorne effect—performing differently when being observed. This group of patients had very extensive surgical haemostasis before we started with the 5 minutes bleeding time, much longer than usual. The surgeons may have perceived that they were a better surgeon if they were not included in the trial, and also that after closure of the chest the microvascular bleeding was now the problem for the anaesthesiologist.

The patients were randomised to receive either the placebo or the intervention drug in doses between 60ml and 250ml. The fibrinogen doses were calculated based on plasma fibrinogen levels at the end of cardiopulmonary bypass (Figure 2).

### Results

#### Primary outcome

Among patients with intraoperative bleeding who received infusion of fibrinogen concentrate, compared with placebo, there was no significant difference in blood loss measured from the time of the fibrinogen infusion and chest closure (p = 0.19) (Table 1).

#### Fibrinogen group

- Median (IQR), mL
  - Fibrinogen: 50 (29-100)
  - Control: 70 (33-145)
- Absolute difference: 20 mL (95% CI, −13 to 35)
- P Value: 0.19

#### Control group

- Median (IQR), mL
  - Fibrinogen: 70 (33-145)
  - Control: 90 (46-149)
- Absolute difference: 20 mL (95% CI, −13 to 35)
- P Value: 0.19

#### Secondary or Exploratory Outcome

<table>
<thead>
<tr>
<th>Time Point</th>
<th>Fibrinogen (n = 58)</th>
<th>Control (n = 59)</th>
<th>Absolute Difference (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0-1 h</td>
<td>70 (35-130)</td>
<td>90 (46-149)</td>
<td>-20 (−35 to 15)</td>
</tr>
<tr>
<td>&gt;1-3 h</td>
<td>80 (50-156)</td>
<td>110 (60-220)</td>
<td>-30 (−45 to 0)</td>
</tr>
<tr>
<td>&gt;3-6 h</td>
<td>100 (54-169)</td>
<td>110 (60-208)</td>
<td>-10 (−15 to 5)</td>
</tr>
<tr>
<td>&gt;6-12 h</td>
<td>110 (80-160)</td>
<td>125 (83-224)</td>
<td>-15 (−20 to 5)</td>
</tr>
<tr>
<td>&gt;12-24 h</td>
<td>130 (80-180)</td>
<td>160 (90-270)</td>
<td>-30 (−35 to 5)</td>
</tr>
<tr>
<td>Cumulative 24-h blood loss</td>
<td>570 (398-730)</td>
<td>690 (400-1090)</td>
<td>-120 (−135 to 35)</td>
</tr>
</tbody>
</table>

#### Table 1. Primary, secondary and exploratory study outcomes

#### Table 2. Secondary transfusion outcomes

<table>
<thead>
<tr>
<th>Patients who received transfusion between intervention and chest closure, No. (%)</th>
<th>Fibrinogen (n = 58)</th>
<th>Control (n = 59)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red blood cells</td>
<td>0</td>
<td>3 (5)</td>
</tr>
<tr>
<td>Fresh-frozen plasma</td>
<td>0</td>
<td>1 (2)</td>
</tr>
<tr>
<td>Platelets</td>
<td>2 (3)</td>
<td>2 (3)</td>
</tr>
<tr>
<td>Any transfusion</td>
<td>2 (3)</td>
<td>4 (7)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patients transfused between intervention and 24 h, thereafter, No. (%)</th>
<th>Fibrinogen (n = 58)</th>
<th>Control (n = 59)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red blood cells</td>
<td>10 (17)</td>
<td>20 (33)</td>
</tr>
<tr>
<td>Fresh-frozen plasma</td>
<td>9 (15)</td>
<td>13 (22)</td>
</tr>
<tr>
<td>Platelets</td>
<td>9 (15)</td>
<td>13 (22)</td>
</tr>
<tr>
<td>Any transfusion</td>
<td>20 (33)</td>
<td>23 (38)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Transfusion units between intervention and 24 h thereafter, median (IQR)</th>
<th>Fibrinogen (n = 58)</th>
<th>Control (n = 59)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Red blood cell transfusion units</td>
<td>0 (0-1)</td>
<td>0 (0-4)</td>
</tr>
<tr>
<td>Fresh-frozen plasma transfusion units</td>
<td>0 (0-2)</td>
<td>0 (0-4)</td>
</tr>
<tr>
<td>Platelets transfusion units</td>
<td>0 (0-1)</td>
<td>0 (0-1)</td>
</tr>
<tr>
<td>Any transfusion units</td>
<td>0 (0-2)</td>
<td>0 (0-8)</td>
</tr>
</tbody>
</table>

Units of RBCs, FFP or platelet concentrate.

The intervention was considered to have started on initiation of infusion of the study medication (Figure 1) (see p. V).

Over the four years of the trial, over 700 patients had complex cardiac surgery, of which 40% were eligible for the trial. Of the eligible patients, 43% did not agree to participate; 203 patients agreed to participate, of which 73 (36%) experienced no intraoperative bleeding and 10 were excluded for other reasons. We suggest that the high number of patients that experienced no intraoperative bleeding may be due to the Hawthorne effect—performing differently when being observed. This group of patients had very extensive surgical haemostasis before we started with the 5 minutes bleeding time, much longer than usual. The surgeons may have perceived that they were a better surgeon if they were not included in the trial, and also that after closure of the chest the microvascular bleeding was now the problem for the anaesthesiologist.

The patients were randomised to receive either the placebo or the intervention drug in doses between 60ml and 250ml. The fibrinogen doses were calculated based on plasma fibrinogen levels at the end of cardiopulmonary bypass measured using the Clauss method (Figure 2).
The duration of primary outcome collection was 4.2 minutes (95% CI, 0.4-8.0 minutes) in the fibrinogen group and 8.7 minutes (95% CI, 5.2-12.1 minutes) in the control group. However, other than these times do suggest these were not the best and fastest surgeons ever. This is why the primary endpoint was different than we expected. We expected that the moment there is a bleeding patient everyone would wait for closure and this would lead to a difference in blood loss in the patient and of course a difference in the intraoperative time factor.

**Secondary outcomes**

There were fewer patients in the fibrinogen group and fewer units of blood units used (Table 2). However, the study was not adequately powered to test the secondary outcomes. The percentage of reduction in transfusion is shown in Figure 3.

After surgery, a single patient (2%) in the fibrinogen group and 6 patients (10%) in the control group received additional fibrinogen concentrate. This confounds the effect on overall outcomes.

**Clinical adverse events within 30 days**

There were more adverse events in the fibrinogen group (Table 4). Two patients died, and 4 suffered a stroke. One patient in the control group suffered a stroke, and one a transient ischaemic attack. The trial was not designed to evaluate major adverse cardiac events and there was no screening for embolic risk aortic disease.

Almost 50% (9/19) of adverse events occurred in two patients (Table 5) (see p. VIII). Also one stroke occurred in a placebo patient with a fibrinogen level of 0.6g/l.

**Transfusion protocol for cardiac surgery**

At Isala Clinics we now use the following transfusion protocol (Figure 5) (see p. VIII). We conduct viscoelastic tests (ROTEM) to guide haemostatic therapies. Maegele and colleagues have provided a useful haemotherapy algorithm (Maegele et al. 2017).

**Conclusion**

Fibrinogen is effective after complex cardiac surgery in the bleeding patient. Based on the current trial data, fibrinogen is recommended as a first-line therapy with target plasma level 2.5g/L at the moment there is an idea of microvascular bleeding in these patients. Both visco-elasticity as the conventional Clauss method can be used to determine the level of fibrinogen at the end of bypass surgery and to optimise further treatment.

We have the tools and knowledge now to change transfusion management. But changing transfusion management, as with any change, is a major behavioural process. You need to do this together with your own multidisciplinary group, using a change strategy such as the Kotter model (https://www.kotterinternational.com/8-steps-process-for-leading-change).

**Conflict of Interest**

Arno Nierich is the principal investigator for the fibrinogen concentrate trial at Isala Clinics. CSL Behring sponsored the study and donated the bottles of study medication.
**Table 5.** Data on clinical adverse events, with allocated treatment, infused dose, fibrinogen plasma concentrations and time of event in days after surgery

<table>
<thead>
<tr>
<th>Participant</th>
<th>Medication</th>
<th>Pre-infusion fibrinogen g/L</th>
<th>Infusion dose g/L</th>
<th>Post-infusion fibrinogen g/L</th>
<th>Clinical adverse events</th>
</tr>
</thead>
<tbody>
<tr>
<td>H-012</td>
<td>fibrinogen</td>
<td>1.6</td>
<td>3</td>
<td>2.4</td>
<td>day +10 day +1 day +2 day 0</td>
</tr>
<tr>
<td>H-161</td>
<td>fibrinogen</td>
<td>0.8</td>
<td>6</td>
<td>1.7</td>
<td>day +5 day +1 day +2 day 0</td>
</tr>
<tr>
<td>H-047</td>
<td>placebo</td>
<td>0.5</td>
<td>7</td>
<td>0.6</td>
<td>day 0</td>
</tr>
<tr>
<td>H-140</td>
<td>fibrinogen</td>
<td>1.6</td>
<td>4</td>
<td>2.3</td>
<td>day +1 day &lt;30</td>
</tr>
<tr>
<td>H-155</td>
<td>fibrinogen</td>
<td>2.4</td>
<td>0</td>
<td>2.3</td>
<td>day +6</td>
</tr>
</tbody>
</table>

MI: myocardial infarction; RI: renal insufficiency or failure; TIA: transient ischemic attack.

a Plasma fibrinogen concentration at end-CPB.
b Infusion of study medication after removal of cardiopulmonary bypass. For placebo matched number of syringes is infused.
c Plasma fibrinogen concentration at ICU admission.

Reproduced with permission from JAMA. 2017;317(7):738-47. ©2017 American Medical Association. All rights reserved.

**Figure 5.** Transfusion protocol for cardiac surgery

**Key Points**
- Implement transfusion management with change strategy
- Multidisciplinary group essential
- Point-of-care and lab monitoring:
  - Part of overcoming the ‘blind spot’ of coagulation management in operating room and intensive care unit
  - Additional tool in fine-tuning bleeding management
  - Measure fibrinogen level by Clauss as first potential bleeding indication
- Fibrinogen is effective after complex cardiac surgery in the bleeding patient; from rescue medication to first-line therapy with target level 2.5 g/L in the bleeding patient

**References**


